•
Antibodies targeting extracellular tau have been proposed as a therapeutic strategy to reduce the spread of pathology and slow the progression of Alzheimer’s disease1,2
•
MK-2214 is a novel, highly potent, antibody targeting phosphorylated serine 413 (pS413) containing tau which is present in pathological forms of tau3
•
In vitro and in vivo seeding studies showed robust reductions in tau pathology with antibodies targeting pS413 tau, suggesting that reducing extracellular pS413 tau can reduce the extracellular spread of tau seeds3
•
Studies in non-human primates demonstrated that MK-2214 has an extended half-life compared to traditional antibodies3

MK-2214 has a favorable pharmacological profile as an antibody to slow the progression of Alzheimer’s disease
–
Long half-life of approximately 80 days
–
Single dose administration in healthy participants, and multiple dose administration in participants with mild-to-moderate cognitive impairment,
well-tolerated at doses that produced near-saturating binding of free pS413 tau
•
An ongoing phase 2 trial is evaluating MK-2214 for slowing the progression of tau spreading in people with early Alzheimer’s disease (NCT07033494)